Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3 [Seeking Alpha]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Seeking Alpha
Xdemvy remains the only approved treatment for Demodex blepharitis, with accelerating sales growth and significant untapped patient population in the U.S. TARS is poised for further upside from global expansion, robust pipeline, and an earnings inflection expected in 2026 as revenue growth achieves profitability. With durable recurring revenue and low competition, TARS is expected to outperform the market as Xdemvy's growth trajectory continues. Wirestock/iStock via Getty Images In March , I penned an article highlighting Tarsus Pharmaceuticals, Inc. TARS ) as a Buy due to rapid commercialization of Xdemvy following FDA approval in July 2023 . Since, the stock has appreciated from This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of TARS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeki
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]Yahoo! Finance
- Tarsus to Participate in Upcoming Investor ConferenceGlobeNewswire
- Tarsus Pharmaceuticals (NASDAQ:TARS) is now covered by analysts at Mizuho. They set an "outperform" rating and a $100.00 price target on the stock.MarketBeat
- Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
TARS
Earnings
- 11/4/25 - Beat
TARS
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- TARS's page on the SEC website